Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 632 across all filing types
Latest filing 2023-09-25 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司2023年第二次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as meeting materials for the "2023 Second Extraordinary General Meeting" of Jiangsu Haobo Biomedical Co., Ltd. It contains detailed meeting instructions, agenda, and proposals to be discussed and voted on during the shareholders' meeting. The content includes procedural rules, voting rights, and specific agenda items such as approval of a 2023 restricted stock incentive plan and related authorizations. This is clearly a set of materials prepared for a shareholders' meeting, not the minutes or results of the meeting, nor a financial report or announcement. Therefore, it fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting or Extraordinary General Meeting.
2023-09-25 Chinese
江苏浩欧博生物医药股份有限公司监事会关于公司2023年限制性股票激励计划首次授予部分激励对象名单的公示情况说明及核查意见
Regulatory Filings Classification · 95% confidence The document is a public announcement by the supervisory board regarding the 2023 restricted stock incentive plan and the initial list of incentive recipients. It includes details about the internal verification and compliance with relevant laws and regulations. The content focuses on disclosure and verification of stock incentive plan participants rather than financial results, management changes, or other report types. The document length is short (1640 characters) and is an announcement of the incentive plan and related verification, not a full report or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement related to stock incentive plans.
2023-09-25 Chinese
江苏浩欧博生物医药股份有限公司关于独立董事公开征集委托投票权的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement by Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding the public solicitation of proxy voting rights by an independent director for the company's 2023 second extraordinary general meeting of shareholders. It details the solicitation process, the voting agenda related to a 2023 restricted stock incentive plan, the voting period, and instructions for shareholders to submit proxy votes. The document does not contain financial statements or results but is a formal announcement related to shareholder voting rights and meeting arrangements. It is not a report of the meeting results, nor a financial report or management discussion. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) as it concerns the solicitation and exercise of voting rights for a shareholder meeting agenda.
2023-09-14 Chinese
江苏浩欧博生物医药股份有限公司2023年限制性股票激励计划（草案）摘要公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding a 2023 restricted stock incentive plan (股权激励计划) by 江苏浩欧博生物医药股份有限公司. It includes specifics about the stock incentive plan, such as the number of shares, pricing, eligibility, vesting conditions, performance targets, and legal compliance. The document references regulatory frameworks like the Company Law, Securities Law, and Shanghai Stock Exchange listing rules, and discusses the plan's approval process including board and shareholder meetings. This is a corporate announcement about a capital change related to issuing new shares to employees as part of a stock incentive plan. It is not a financial report, earnings release, or management discussion. It is not a proxy statement or voting result announcement. The content fits best under the category of Share Issue/Capital Change (SHA), as it announces a new share issuance plan for employee incentives.
2023-09-14 Chinese
江苏浩欧博生物医药股份有限公司第三届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Jiangsu Haobo Biopharmaceutical Co., Ltd. It details the approval of a 2023 restricted stock incentive plan and related management and authorization matters. The document includes voting results and references to further shareholder meetings for approval. It does not contain financial statements or detailed financial performance data. It is a corporate governance announcement related to board decisions and management proposals, specifically about stock incentive plans and board meeting resolutions. Therefore, it fits best under Board/Management Information (MANG). The document length is 3364 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full report or presentation.
2023-09-14 Chinese
江苏浩欧博生物医药股份有限公司2023年限制性股票激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled as the '2023 Restricted Stock Incentive Plan Implementation Assessment Management Measures' of Jiangsu Haobo Biopharmaceutical Co., Ltd. It details the purpose, principles, scope, assessment institutions, performance indicators, assessment periods, procedures, and management of the assessment related to a restricted stock incentive plan. The content focuses on the company's internal incentive mechanism, performance evaluation criteria, and governance related to stock incentives for employees and management. There is no indication that this is a financial report, earnings release, or regulatory filing. It is not an announcement of voting results or a proxy statement. The document is a detailed governance and management policy related to stock incentives, which aligns with governance information about internal rules and board/management practices. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 4241 characters, which is substantive and contains detailed policy content, not a brief announcement or certification.
2023-09-14 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.